Jiangzhong Pharmaceutical Co Ltd (600750) - Net Assets

Latest as of December 2025: CN¥4.70 Billion CNY ≈ $688.21 Million USD

Based on the latest financial reports, Jiangzhong Pharmaceutical Co Ltd (600750) has net assets worth CN¥4.70 Billion CNY (≈ $688.21 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.88 Billion ≈ $1.01 Billion USD) and total liabilities (CN¥2.18 Billion ≈ $318.67 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Jiangzhong Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥4.70 Billion
% of Total Assets 68.35%
Annual Growth Rate 16.92%
5-Year Change 2.63%
10-Year Change 79.8%
Growth Volatility 84.65

Jiangzhong Pharmaceutical Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Jiangzhong Pharmaceutical Co Ltd for the complete picture of this company's asset base.

Annual Net Assets for Jiangzhong Pharmaceutical Co Ltd (1993–2025)

The table below shows the annual net assets of Jiangzhong Pharmaceutical Co Ltd from 1993 to 2025. For live valuation and market cap data, see how much is Jiangzhong Pharmaceutical Co Ltd worth.

Year Net Assets Change
2025-12-31 CN¥4.70 Billion
≈ $688.21 Million		 +5.18%
2024-12-31 CN¥4.47 Billion
≈ $654.34 Million		 -3.39%
2023-12-31 CN¥4.63 Billion
≈ $677.30 Million		 +2.68%
2022-12-31 CN¥4.51 Billion
≈ $659.65 Million		 -1.63%
2021-12-31 CN¥4.58 Billion
≈ $670.56 Million		 +7.79%
2020-12-31 CN¥4.25 Billion
≈ $622.10 Million		 +8.33%
2019-12-31 CN¥3.92 Billion
≈ $574.26 Million		 +20.62%
2018-12-31 CN¥3.25 Billion
≈ $476.08 Million		 +11.60%
2017-12-31 CN¥2.92 Billion
≈ $426.61 Million		 +11.45%
2016-12-31 CN¥2.62 Billion
≈ $382.77 Million		 +11.09%
2015-12-31 CN¥2.35 Billion
≈ $344.55 Million		 +10.38%
2014-12-31 CN¥2.13 Billion
≈ $312.15 Million		 -0.01%
2013-12-31 CN¥2.13 Billion
≈ $312.16 Million		 +3.90%
2012-12-31 CN¥2.05 Billion
≈ $300.43 Million		 +7.06%
2011-12-31 CN¥1.92 Billion
≈ $280.62 Million		 +7.79%
2010-12-31 CN¥1.78 Billion
≈ $260.34 Million		 +65.82%
2009-12-31 CN¥1.07 Billion
≈ $157.00 Million		 +10.68%
2008-12-31 CN¥969.41 Million
≈ $141.86 Million		 +15.69%
2007-12-31 CN¥837.97 Million
≈ $122.62 Million		 +11.93%
2006-12-31 CN¥748.62 Million
≈ $109.55 Million		 +6.62%
2005-12-31 CN¥702.13 Million
≈ $102.74 Million		 +5.93%
2004-12-31 CN¥662.81 Million
≈ $96.99 Million		 +3.60%
2003-12-31 CN¥639.80 Million
≈ $93.62 Million		 +11.23%
2002-12-31 CN¥575.21 Million
≈ $84.17 Million		 +4.38%
2001-12-31 CN¥551.04 Million
≈ $80.63 Million		 +0.97%
2000-12-31 CN¥545.76 Million
≈ $79.86 Million		 +5.75%
1999-12-31 CN¥516.08 Million
≈ $75.52 Million		 +85.73%
1998-12-31 CN¥277.86 Million
≈ $40.66 Million		 +13.20%
1997-12-31 CN¥245.46 Million
≈ $35.92 Million		 +11.89%
1996-12-31 CN¥219.37 Million
≈ $32.10 Million		 +488.19%
1995-12-31 CN¥37.30 Million
≈ $5.46 Million		 +8.55%
1994-12-31 CN¥34.36 Million
≈ $5.03 Million		 +8.53%
1993-12-31 CN¥31.66 Million
≈ $4.63 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Jiangzhong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 263645865300.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥2.64 Billion 65.54%
Common Stock CN¥634.95 Million 15.78%
Other Comprehensive Income CN¥436.74 Million 10.86%
Other Components CN¥314.66 Million 7.82%
Total Equity CN¥4.02 Billion 100.00%

Jiangzhong Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangzhong Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Jafron Biomedical Co Ltd
SHE:300529
 $2.23 Billion
Guodian Nanjing Automation Co Ltd
SHG:600268
 $2.23 Billion
Ashtrom Group Ltd
TA:ASHG
 $2.23 Billion
Mayora Indah Tbk
JK:MYOR
 $2.23 Billion
OKE Precision Cutting Tools Co. Ltd. A
SHG:688308
 $2.22 Billion
SPS Commerce Inc
NASDAQ:SPSC
 $2.22 Billion
DO & CO Aktiengesellschaft
VI:DOC
 $2.22 Billion
Melco Resorts & Entertainment Ltd
NASDAQ:MLCO
 $2.22 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangzhong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,862,808,649 to 4,022,814,419, a change of 160,005,770 (4.1%).
  • Net income of 906,120,000 contributed positively to equity growth.
  • Dividend payments of 777,950,524 reduced retained earnings.
  • Other comprehensive income increased equity by 3,163,293.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥906.12 Million +22.52%
Dividends Paid CN¥777.95 Million -19.34%
Other Comprehensive Income CN¥3.16 Million +0.08%
Other Changes CN¥28.67 Million +0.71%
Total Change CN¥- 4.14%

Book Value vs Market Value Analysis

This analysis compares Jiangzhong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.77x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 396.71x to 3.77x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.06 CN¥23.92 x
1994-12-31 CN¥0.07 CN¥23.92 x
1995-12-31 CN¥0.07 CN¥23.92 x
1996-12-31 CN¥0.42 CN¥23.92 x
1997-12-31 CN¥0.47 CN¥23.92 x
1998-12-31 CN¥0.53 CN¥23.92 x
1999-12-31 CN¥0.98 CN¥23.92 x
2000-12-31 CN¥1.00 CN¥23.92 x
2001-12-31 CN¥1.00 CN¥23.92 x
2002-12-31 CN¥1.05 CN¥23.92 x
2003-12-31 CN¥1.15 CN¥23.92 x
2004-12-31 CN¥1.26 CN¥23.92 x
2005-12-31 CN¥1.33 CN¥23.92 x
2006-12-31 CN¥1.22 CN¥23.92 x
2007-12-31 CN¥1.35 CN¥23.92 x
2008-12-31 CN¥1.49 CN¥23.92 x
2009-12-31 CN¥1.65 CN¥23.92 x
2010-12-31 CN¥2.78 CN¥23.92 x
2011-12-31 CN¥2.85 CN¥23.92 x
2012-12-31 CN¥3.06 CN¥23.92 x
2013-12-31 CN¥3.16 CN¥23.92 x
2014-12-31 CN¥3.25 CN¥23.92 x
2015-12-31 CN¥3.73 CN¥23.92 x
2016-12-31 CN¥4.25 CN¥23.92 x
2017-12-31 CN¥4.61 CN¥23.92 x
2018-12-31 CN¥5.19 CN¥23.92 x
2019-12-31 CN¥5.68 CN¥23.92 x
2020-12-31 CN¥6.14 CN¥23.92 x
2021-12-31 CN¥6.33 CN¥23.92 x
2022-12-31 CN¥6.18 CN¥23.92 x
2023-12-31 CN¥5.44 CN¥23.92 x
2024-12-31 CN¥6.13 CN¥23.92 x
2025-12-31 CN¥6.35 CN¥23.92 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangzhong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 22.52%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 21.47%
  • • Asset Turnover: 0.61x
  • • Equity Multiplier: 1.71x
  • Recent ROE (22.52%) is above the historical average (15.32%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 59.03% 8.74% 2.82x 2.40x CN¥15.52 Million
1994 39.29% 5.75% 2.82x 2.42x CN¥10.06 Million
1995 39.40% 4.35% 3.14x 2.89x CN¥10.97 Million
1996 11.81% 11.18% 0.72x 1.48x CN¥3.97 Million
1997 10.30% 11.56% 0.53x 1.68x CN¥736.95K
1998 11.19% 16.81% 0.44x 1.52x CN¥3.30 Million
1999 5.66% 22.47% 0.19x 1.31x CN¥-22.38 Million
2000 0.11% 0.15% 0.52x 1.35x CN¥-51.76 Million
2001 7.22% 10.65% 0.56x 1.22x CN¥-14.54 Million
2002 7.86% 6.47% 0.90x 1.35x CN¥-11.76 Million
2003 8.42% 5.39% 0.95x 1.64x CN¥-9.49 Million
2004 6.53% 5.17% 0.72x 1.76x CN¥-22.89 Million
2005 7.66% 5.48% 0.85x 1.64x CN¥-16.37 Million
2006 10.50% 6.64% 0.90x 1.76x CN¥3.71 Million
2007 11.67% 8.36% 0.96x 1.46x CN¥14.01 Million
2008 16.30% 10.30% 0.92x 1.72x CN¥58.06 Million
2009 19.59% 10.64% 1.18x 1.56x CN¥98.44 Million
2010 15.08% 10.19% 1.02x 1.45x CN¥87.99 Million
2011 12.21% 8.61% 1.02x 1.39x CN¥41.16 Million
2012 11.26% 7.06% 0.99x 1.61x CN¥25.29 Million
2013 8.28% 6.20% 0.93x 1.44x CN¥-35.68 Million
2014 12.75% 9.34% 0.85x 1.60x CN¥57.12 Million
2015 15.59% 14.13% 0.97x 1.14x CN¥131.58 Million
2016 14.52% 24.53% 0.50x 1.17x CN¥118.21 Million
2017 14.33% 23.92% 0.52x 1.15x CN¥126.28 Million
2018 14.45% 26.79% 0.46x 1.17x CN¥144.92 Million
2019 13.02% 18.93% 0.51x 1.34x CN¥107.53 Million
2020 12.22% 19.40% 0.50x 1.27x CN¥86.05 Million
2021 12.63% 17.60% 0.48x 1.50x CN¥105.38 Million
2022 15.38% 15.40% 0.62x 1.61x CN¥209.14 Million
2023 18.38% 15.78% 0.71x 1.64x CN¥327.69 Million
2024 20.40% 17.77% 0.68x 1.68x CN¥401.91 Million
2025 22.52% 21.47% 0.61x 1.71x CN¥503.84 Million

Industry Comparison

This section compares Jiangzhong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,347,197,696
  • Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jiangzhong Pharmaceutical Co Ltd (600750) CN¥4.70 Billion 59.03% 0.46x $2.22 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $2.84 Billion -41.97% 9.13x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.05 Billion 10.46% 0.19x $5.18 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.81 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $5.08 Billion 1.71% 1.08x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $141.91 Million 11.01% 0.32x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $994.58 Million 2.01% 2.11x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $332.48 Million 26.89% 0.68x $3.30 Billion

About Jiangzhong Pharmaceutical Co Ltd

SHG:600750 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.22 Billion
CN¥15.20 Billion CNY
Market Cap Rank
#5878 Global
#1246 in China
Share Price
CN¥23.92
Change (1 day)
-0.25%
52-Week Range
CN¥21.21 - CN¥27.69
All Time High
CN¥561.13
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsu… Read more